Arbutus Biopharma Corp (ABUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
Sales | 1,726 | 1,532 | 2,145 | 4,658 | 4,651 |
Gross Profit | 1,726 | 1,532 | 2,145 | 4,658 | 4,651 |
Operating Expenses | 23,309 | 20,895 | 22,892 | 26,216 | 23,036 |
Operating Income | -21,583 | -19,363 | -20,747 | -21,558 | -18,385 |
Interest Expense | 34 | 44 | 44 | 46 | 171 |
Other Income | 1,821 | 1,532 | 1,479 | 1,500 | 1,462 |
Pre-tax Income | -19,796 | -17,875 | -19,312 | -20,104 | -17,094 |
Net Income Continuous | -19,796 | -17,875 | -19,312 | -20,104 | -17,094 |
Net Income | $-19,796 | $-17,875 | $-19,312 | $-20,104 | $-17,094 |
EPS Basic Total Ops | -0.11 | -0.10 | -0.12 | -0.12 | -0.10 |
EPS Basic Continuous Ops | -0.11 | -0.10 | -0.11 | -0.12 | -0.10 |
EPS Diluted Total Ops | -0.11 | -0.10 | -0.12 | -0.12 | -0.10 |
EPS Diluted Continuous Ops | -0.11 | -0.10 | -0.11 | -0.12 | -0.10 |
EPS Diluted Before Non-Recurring Items | -0.11 | -0.10 | -0.12 | -0.12 | -0.10 |
EBITDA(a) | $-21,227 | $-19,008 | $-20,388 | $-21,189 | $-18,043 |